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Abstract
CRISPR-Cas9 has quickly become the method of choice for genome editing, with multiple publications describ-
ing technical advances and novel applications. It has been widely adopted as a tool for basic research and has
significant translational and clinical potential. However, its usage has outpaced the establishment of essential and
rigorous controls for unwanted off-target effects, manifested as small mutations, large deletions of target loci, or
large-scale chromosomal rearrangements. A common application of CRISPR-Cas9 is as a tool for creating isogenic
cell-line models to study the effects of precise mutations, or variants, on disease traits. Here, we describe the ef-
fect of standard CRISPR-Cas9 mutagenesis protocols on well characterized cancer cell lines. We demonstrate that
commonly used methods for detecting correctly mutated clones fail to uncover large-scale rearrangements. We
show that simple cytogenetic methods can be used to identify clones carrying chromosomal abnormalities and
large mutations at target loci. These methods are quick and cost-efficient, and we suggest that such controls
should be performed prior to publication of studies based on novel CRISPR-Cas9 mutated cancer cell lines.
Introduction
Since the landmark publications by the Doudna, Char-
pentier, Siksnys, Zhang, Joung, and Church labs in
2013, CRISPR-Cas9 has utterly revolutionized the field
of biology.1 There are many reasons why the adoption
of the technology has been so swift: its ease of use, low
cost, flexibility, and, undoubtedly, its immediate and ob-
vious application to so many current scientific questions.
The potential clinical applications of CRISPR-Cas9 are
many and varied, although the ethical questions they
raise are complicated.2,3
However, like any novel technique, CRIPSR-Cas9 has
imperfections, most importantly its propensity to cause
off-target mutations, both small and large scale. Authors
and reviewers have sometimes neglected the need for
rigorous screening for such errors, and this must be
addressed before the technique can be relied upon and
advanced to the clinic. From the early stages of its de-
velopment, researchers have identified the ability of
the CRISPR-Cas9 machinery to tolerate mismatches in
the guide sequence.4,5 Improvements in synthetic guide
RNA (sgRNA) design algorithms, the modified Cas9
nickase system that utilizes two guide sequences to in-
crease specificity, and sequencing of all predicted off-
target regions in correctly mutated cells all aim to reduce
mutations at loci with homology to selected guide se-
quences.6 However, more recently, there has been a se-
ries of publications describing large-scale deletions at
or near the target loci.7,8 This type of undesired effect
is much harder to avoid and can go undetected using
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standard screening methods. Kosicki et al. and Shin et al.
used long-range polymerase chain reactions (PCRs)
and long-read sequencing technologies to identify the
changes. While such sequencing technologies are power-
ful, they are not yet universally available. Interestingly,
Paulis et al.9 reported a fluorescence in situ hybridization
(FISH)-based method to detect off-target donor plasmid
integrations in CRISPR-Cas9 targeted mouse embryonic
stem cells. They noted that these integrations occurred
frequently but rarely at predicted off-target loci, and
suggested that the integrations occurred at the sites of
spontaneous double-strand breaks rather than those gen-
erated by Cas9. Ideally, therefore, CRISPR-Cas9 clones
required for downstream analysis should be tested
for all types of off-target events by whole-genome se-
quencing. Clearly, quicker pre-screening methods are
desirable so that only a few clones need to be checked
by this relatively high-cost and analytically intensive
technique.
We and others are interested in using CRISPR-Cas9 to
mutate well-characterized cancer cell lines in order to
generate isogenic control and test cell lines to investigate
mutations and variants associated with colorectal cancer
(CRC) predisposition or treatment resistance. One of the
major goals of creating isogenic cell lines by genome
editing is to generate highly specific mutations in endog-
enous loci without needing to introduce selectable mark-
ers or additional insertions such as loxP sites. These cell
lines can then be used to study the mechanistic effects of
commonly occurring cancer mutations, risk variants, or
combinations thereof, and ultimately as tools for devel-
oping personalized therapeutics. If there are unexpected
and uncharacterized differences between parental and
mutated cells, downstream analyses can easily give rise
to flawed or misinterpreted results. Cancer cell lines
have increased levels of genomic instability when com-
pared to the primary cells and cell lines with stable kar-
yotypes that have been used in the development of
CRISPR methodologies. The effects of CRISPR-Cas9
mutagenesis on chromosomally unstable cells has not
been fully investigated, heightening the importance of
controlling for off-target or undesired mutations.
Here, we describe a number of different CRISPR-Cas9
mutation experiments on cancer cell lines. We identified
clones carrying desired mutations according to standard
Sanger sequencing in all cases. However, cytogenetic an-
alyses including karyotyping and locus-specific FISH
revealed widespread genomic instability in some cor-
rectly targeted clones. In addition, FISH revealed large-
scale deletions and disruptions of the targeted locus that
were undetectable using screening PCRs and Sanger se-
quencing. These rearrangements are specific to individual
clones and vary between cell lines with different levels of
chromosomal instability (CIN).
Methods
Cell lines and cell culture
COLO320 cells were grown in RPMI-1640, and HCC2998
and SW1463 cells were grown in Dulbecco’s modified
Eagle’s medium, supplemented with 10% fetal bovine
serum and 1% penicillin streptomycin (Sigma–Aldrich)
at 37C in 5% CO2. Cells were regularly tested for myco-
plasma contamination. HCT116 wild type and HCT116E79K
cells were purchased fromDharmacon Horizon Discovery.
CRISPR-Cas9 mutation
sgRNA templates to mutate the MLH1 and POLE loci
were designed using the Zhang laboratory online tool
(see Supplementary Table S1 for sequences), and single-
stranded DNA oligos were synthesized. These were
annealed and cloned into CRISPR-Cas9 vectors contain-
ing wild-type spCas (px330) and Cas9 nickase (px355)
previously modified to contain puromycin selectable
markers (kind gifts from Dr. Ben Davies, Wellcome
Centre for Human Genetics, University of Oxford,
Oxford, United Kingdom) according to online protocols
(https://www.addgene.org/crispr/zhang/). Homology di-
rected repair (HDR) templates, designed as single-
stranded oligos complementary to the sgRNA, contained
the desired sequence change and 70 bp homology arms
(Eurogentec; Supplementary Table S2). Predesigned Edit-
R sgRNAs to mutate NFE2L2, tracrRNAs, and hCMV-
PuroR-Cas9 expression plasmid were purchased from
Dharmacon Horizon Discovery. Plasmids and RNAs
were transfected into the cell lines using Lipofectamine
2000 (Invitrogen) or Dharmafect (Dharmacon) according
to the manufacturers’ instructions. Puromycin was
added 24 h post transfection at concentrations from 1 to
10lg/mL and replaced daily until all control green
fluorescent protein (GFP) transfected cells were killed.
CRISPR-Cas9 transfected cells were then diluted to a
concentration of 1 cell per well and the resultant single-
cell clones amplified, replica plated, and DNA extracted
for screening.
Cas9 ribonuclear protein delivery
SgRNAs were synthesized using an Engen sgRNA syn-
thesis kit (New England Biolabs) according to the manu-
facturer’s instructions and purified using Zymo-Spin IC
Columns (Zymo Research; see Supplementary Table S1
for sequences). A non-targeting control sg-RNA supplied
with the Engen kit uses a sequence from the tetR(C) gene
in the pBR322 plasmid that is not found in the human
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genome. The most similar human sequence has three mis-
matches. RNP complexes with Cas9 protein (New Eng-
land Biolabs) and synthesized sgRNAs were made and
mixed with HDR template (Supplementary Table S2) im-
mediately prior to transfection by electroporation with
an Amaxa 4D-Nucleofector (Lonza), carried out us-
ing program CM-150 and SG cell line kit (Lonza)
according to the manufacturer’s instructions. Forty-
eight hours post transfection, cells were diluted to a
concentration of 1 cell per well and the resultant single-
cell clones amplified, replica plated, and DNA extracted
for screening.
Mutation screening by PCR and Sanger sequencing
PCR was used to amplify the target loci (see Supplemen-
tary Table S1 for primers). Purified PCR products were
sequenced by standard Sanger technology (Zoology
Sequencing facility, University of Oxford). Sequences
were analyzed for quality of trace, aligned to reference se-
quences with the open source ‘‘A plasmid Editor’’ (ApE
v2.0.55), and manually inspected for desired and unde-
sired sequence changes by two independent researchers.
Preparation of metaphase spreads and DAPI staining
Chromosome spreads were harvested using standard tech-
niques. Briefly, Colcemid (Thermo Fisher Scientific) was
added to subconfluent cultures at a final concentration of
50 ng/mL for 3 h. Metaphases were detached by mild tryp-
sinization and swollen in hypotonic solution (KCl 75mM)
before being fixed twice in Carnoy’s fixative. Twenty mi-
croliters of the cell suspension was dropped onto clean
slides and allowed to dry overnight. The slides were
mounted in DAPI/Vectashield (Vector Laboratories).
Images were collected with an Olympus BX-51 micro-
scope, equipped with a JAI CVM4+ CCD camera, using
Leica Cytovision Genus v7.1. Chromosome number was
analyzed in a minimum of 25 metaphases per cell line.
FISH
BAC probes that were not available in-house were pur-
chased from SourceBioscience. The plasmids containing
chromosome-specific centromeric DNA were a kind gift
from Prof. Mariano Rocchi (Bari University, Bari, Italy).
The probes were labeled with the Nick Translation Kit
(Abbott Molecular) according to the manufacturer’s in-
structions, with biotinylated-16-dUTP (Sigma–Aldrich),
Spectrum Red-dUTP (Vysis, Abbott Molecular), Spectrum-
Green dUTP (Vysis, Abbott Molecular), and Spectrum
Gold-dUTP (Enzo Laboratories). The probes were puri-
fied by precipitation, adding a 10· excess of unlabeled
Cot1 DNA (Thermo Fisher Scientific), and re-suspended
in hybridization buffer (50% formamide, 10% dextran
sulfate, 2 ·SSC). The labeled probes were denatured
for 8min at 85C in a thermocycler machine. The BAC/
PAC probes were pre-annealed at 37C for 30min.
Metaphase spread DNA was denatured in NaOH,
0.07M, for 2min. Following dehydration in an alcohol se-
ries, the denatured probe mix was applied to the slides
under a coverslip. The hybridization was carried out over-
night at 37C. Post-hybridization washes were carried out
in 0.1·SSC at 60C. The biotinylated probes were detected
using streptavidin-Cy5 (Thermo Fisher Scientific). The
slides were mounted in DAPI/Vectashield (Vector Labora-
tories) and analyzed with the system described above.
The list of the probes used in this study is shown in
Supplementary Table S3.
Results
We carried out CRISPR-Cas9 mutation on three target
loci using a different CRC cell line for each (Supplemen-
tary Table S1) according to standard protocols (Fig. 1).
The experiments were designed to address questions on
the theme of CRC genetics and therapy. Experiment 1
aimed to introduce a specific point mutation (by HDR)
to mutate a heterozygous single nucleotide polymor-
phism (SNP) rs1800734 in the MLH1 promoter. Experi-
ment 2 aimed to revert a pathogenic point mutation
in the POLE gene to the wild-type sequence by HDR.
Experiment 3 aimed to knock out one copy of the
NFE2L2 gene by causing indels in exon 4. The cell
lines (COLO320, HCC2998, and SW1463) were selected
from publically available resources according to their
SNP genotype or mutation status at our loci of interest.
Experiments 1 and 2 used Cas9 wild-type and nickase
plasmids, respectively, containing sgRNA templates and
puromycin selectable markers. Experiment 3 used a puro-
mycin selectable wild-type Cas9 plasmid together with
synthetic ready-to-use sgRNAs in an attempt to improve
efficiency. For all experiments, the CRISPR-Cas9 ma-
chinery was transfected into cells using lipid based meth-
ods, followed by puromycin selection and single-cell
cloning. Clones were then split into replica plates, with
one kept in culture and DNA extracted from the other
for mutation screening.
CRISPR-Cas9 mutated clones were detected
by Sanger sequencing
Figure 2A shows sequence traces from experiment 1,
suggesting that we correctly mutated the heterozy-
gous A/G SNP creating both GG and AA homozygous
clones. Clones with correct sequences were found with
a frequency of 1.5% (GG) and 2% (AA). In experi-
ment 2, where the double nicking strategy was used,6 cor-
rectly targeted point mutations to revert an existing
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heterozygous mutation to the wild type were found us-
ing Sanger sequencing with an efficiency of 9.5% at
the POLE locus (Fig. 2B). Heterozygous indels in the
NFE2L2 gene were detected in SW1463 cells at an effi-
ciency of 2% (Fig. 2C). PCR primers were designed to
be outside any regions of homology in HDR templates
but to give products easily sequenced by a single Sanger
read covering 200–300 bp, and centered on the sgRNA
template sequence.
Chromosomal analysis showed differences between
CRISPR-Cas9 clones and parental cells
Clones with the desired mutations were amplified, and
metaphase spreads were subjected to cytogenetic analysis
using DAPI staining. We found substantial differences in
chromosome numbers between parental cells and some
CRISPR-Cas9 clones in all three experiments (Fig. 3),
with an increased variability found in the CRISPR-Cas9
clones. In the COLO320 clones, we also observed an in-
crease in the number of double minutes, small fragments
of extrachromosomal DNA, as an additional manifesta-
tion of CIN in clone GG (Fig. 3A, right panel). While
COLO320 and SW1463 (Fig. 3C), like many cancer
cell lines, exhibit aneuploidy, HCC2998 is close to dip-
loid. In the latter, we observed that CRIPSR-Cas9 tar-
geted clones 2 and 3 (Fig. 3B) had the same modal
chromosomal number and very similar overall counts to
the parental cell lines. This suggests that the underlying
instability of the cell line acts together with the CRISPR-
Cas9 machinery to drive large-scale chromosomal rear-
rangements.We confirmed this by analyzing a commercially
available CRISPR-Cas9 mutated clone of the diploid
CIN cell line Hct116. Similar to HCC2998, no large dif-
ferences in chromosome number or karyotype were
FIG. 1. CRIPSR-Cas9 mutation of cell lines: Experimental strategy. Schematic showing (A) CRISPR-Cas9 mutation
design, (B) cell transfection and selection, and (C) mutation screening by Sanger sequencing and cytogenetic clone
analysis
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FIG. 2. CRISPR target loci and Sanger traces showing
expected mutations. (A) Mutation of single nucleotide
polymorphism (SNP) rs1800734 in the MLH1 promoter in
COLO320 cells. The top panel shows the genomic location,
target sequence (orange rectangle), and screening polymerase
chain reaction (PCR) amplicon (green rectangle). The lower
panel shows aligned sequence traces of the parental and two
CRISPR-Cas9 mutated clones. The box shows the position of
the heterozygous (A/G) SNP location and an AA and GG
homozygous trace. (B) Reversion of mutation in POLE exon 9
in HCC2998 cells. The top panel shows the genomic location,
and two target sequences due to the double-nicking strategy
(orange rectangles) and screening PCR amplicon (green
rectangle). The lower panel shows aligned sequence traces of
the parental and a wild-type revertant clone. The box shows
the position of the heterozygous (C to G) mutation location
and a homozygous C (wild type) trace. (C) Knockout of
NFE2L2 exon 4 in SW1463 cells. The top panel shows the
genomic location, target sequence (orange rectangle), and
screening PCR amplicon (green rectangle). The lower panel
shows aligned sequence traces of the parental and clones
with heterozygous deletions obtained from the reverse
sequencing primer (right to left). The box shows the position
of the guide and PAM sequence, within which the clean trace
becomes disrupted due to a deletion.
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observed between the parental and CRISPR-Cas9 mu-
tated clone (Supplementary Fig. S1). It is also possible
that the single-cell cloning process exacerbated existing
CIN, selecting for clones with rearrangements that
enhanced growth under less favorable conditions. In
order to check that the subcloning process alone is
not responsible for all the observed rearrangements,
we subjected COLO320 to single-cell cloning in the ab-
sence of CRISPR-Cas9 machinery and analyzed meta-
phase spreads from five separate clones (Supplementary
Fig. S2A and B). Surprisingly, although each clone was
derived from a single cell, there were already substantial
variations between cells after fewer than 10 passages.
However, the distribution of chromosome number and
double minutes was similar to that seen in the parental
cell population (Fig. 3A). We also wished to confirm
that puromycin treatment alone is not the main factor
in the increased CIN. We therefore treated COLO320
cells with a near lethal dose of puromycin (resulting in
80–90% cell death), followed by single-cell cloning
and chromosome counting. Again, we found that though
the cells varied in chromosome number, the distribution
was more similar to the parental cell population than
those subjected to CRISPR mutagenesis (Supplementary
Fig. S2D).
FISH analysis showed large-scale target
locus-specific rearrangements
Given the observed combination of background and
CRISPR-Cas9 induced CIN, we also wished to investi-
gate any rearrangements within the target locus more di-
rectly attributable to the CRISPR-Cas9 targeting. We
therefore carried out FISH on mutated clones from each
experiment using two or three BAC probes overlapping
and flanking the target locus, together with centromeric
or telomeric probes for the appropriate chromosome
(Supplementary Table S3). Figure 4A shows the FISH
analysis of the parental and CRISPR-Cas9 mutated
COLO320 cells from experiment 1. We detected sig-
nals on both copies of chromosome 3 on the majority
of parental cells, comprising all threeMLH1BAC probes,
and therefore exhibiting the expected labeling pattern for
the diploidMLH1 locus. In contrast, the AA clone had no
cells containing two correct signals. All cells had one cor-
rect signal and one containing the three BAC probes plus
additional labeling with the centromeric probe overlap-
ping the MLH1 locus (Supplementary Fig. S3). Using a
labeled version of the CRISPR-Cas9 px330 vector in a
further FISH experiment, we confirmed that the sig-
nal was in fact due to integration of this vector, probably
in a tandem array, hybridizing to the generic vector se-
quence present in the centromeric probe backbone
(Fig. 4A). Disruption of our target by a large vector insert
likely explained the disappearance of one of the two SNP
alleles within the Sanger sequence (giving the appearance
of an AA homozygote), since the screening PCR primers
failed to amplify across such a large insertion. The GG
clone showed two normal MLH1 signals, although one
had translocated in its entirety to a different unidentified
chromosome. The translocation could have happened as a
result of a double-strand break caused by Cas9 or may
have been present in the parental cell prior to mutation
at very low frequency. Subclones that had not undergone
CRISPR-Cas9 treatment had very few abnormal FISH
signals, with most cells having two complete MLH1
loci on chromosome 3 (Supplementary Fig. S2C).
Further FISH analysis of HCC2998 clones from ex-
periment 2 demonstrated that apparent CRISPR-Cas9
point mutations correcting heterozygous POLE muta-
tions were in fact due to chromosomal truncations in
which the mutated copy of POLE is lost (Fig. 4B). In
clone 1 (and clone 3; data not shown), we observed one
normal POLE locus signal and total loss of the other,
whereas in clone 2, one of the two POLE signals was
‰
FIG. 3. CRIPSR clones exhibit chromosomal instability. (A) Mutation of SNP rs1800734 in the MLH1 promoter
in COLO320 cells. Left panel: graphs showing the chromosome counts per cell of the parental and AA and GG
sequenced clones. The parental cells show a variable number of chromosomes with the modal number of 52.
The mutant clones show a wider distribution and no clear model number. Middle panel: graphs showing the
number of double minutes per cell. The distribution is similar between the parental and AA clones but numbers
are greatly increased in GG cells. Left panel: DAPI-stained metaphase spreads showing double minutes (red
arrows). (B) Reversion of mutation in POLE exon 9 in HCC2998 cells. Graphs showing the chromosome counts per
cell of the parental and clones 1, 2, and 3. The parental cells have a modal number of 47 chromosomes. Clones 2
and 3 also have a modal number of 47 and similar overall distribution. Clone 1 has more variable chromosome
numbers. (C) Mutation of NFE2L2 gene in SW1463 cells. Graphs showing the chromosome counts per cell of the
parental and sequenced clones 5 and 6. The parental cells show a variable number of chromosomes with the
modal number of 49. The mutant clones show a wider distribution and no clear modal number.
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much weaker, suggesting partial truncation of the target
region due to deletion within the probe binding site.
In all clones, we suggest that the cellular machinery
failed to repair a double-strand break at POLE caused
by the CRIPSR-Cas9 machinery. Again, PCR amplifica-
tion would have failed to amplify this truncated locus,
giving rise to Sanger sequence from just one allele
and the appearance of homozygosity. Similar trun-
cations were seen in a separate cell line, SNU81 after
CRISPR-Cas9 POLE targeting (data not shown), so the
phenomenon is not cell-type specific. FISH on clones
from experiment 3 showed frequent fragmentation of chro-
mosome 2 in SW1463 cells (data not shown).
The use of purified Cas9 ribonuclear protein (RNP) de-
livery methods has been shown to be more efficient and
lead to fewer off-target events by several groups.10–13
We therefore repeated experiment 1 using this approach.
Initially, we were encouraged that RNP appeared more ef-
ficient than plasmid-based methods (even without antibi-
otic selection) after screening by Sanger sequencing (6%
AA, 4% GG). However, when we subjected these clones,
and other clones showing heterozygous inserts or deletions
in the region to karyotyping and FISH analysis, we again
found abnormal chromosome counts and FISH signals,
suggesting that even with a short exposure to Cas9 protein,
cancer cells are prone to large rearrangements (Supple-
mentary Figs. S4 and S5 and Supplementary Table S4).
A clone genotyped as AA was polyploid, with most cells
carrying four or more copies of MLH1 (Supplementary
Fig. S4A), and a clone genotyped as GG had lost one
copy of MLH1 and a flanking region in all cells analyzed
(Supplementary Fig. S4B). The clones treated with an off-
target sgRNA had largely normal MLH1 loci, as seen in
the parental cells, confirming that the targeted Cas9
sgRNA complex is crucial for generating large-scale rear-
rangements at the target locus. However, these cells also
displayed more tetraploidy and variable chromosome
counts than untreated clones, confirming that the action
of Cas9, even without a target, can augment the underlying
CIN of the cells (Supplementary Table S4 and Fig. S5).
Discussion
We have shown here that standard CRISPR-Cas9 genome
editing protocols in cancer cell lines with existing CIN
are highly likely to cause unwanted chromosomal rear-
rangements both at the target loci and on other chromo-
somes. We were able to detect these events using
cytogenetic analysis. We specifically used relatively
straightforward methods to demonstrate that rearrange-
ments are easy to detect without specialist resources or
expertise. We used our in-house facility, but there are
similar commercial services readily available. In future
experiments in our own lab, we will now be carrying
out routine analysis to select a subclone of the parental
cell line prior to carrying out CRISPR-Cas9 mutagenesis,
and afterwards on clones with apparently correct mutations
according to Sanger or next-generation sequencing (NGS).
Due to their utility in investigating cancer biology and
therapeutic responses, gene-edited cancer cell lines are
highly desirable.14,15 Clinical adoption of NGS means
‰
FIG. 4. Fluorescence in situ hybridization (FISH) showing abnormal signals at the target loci. (A) Mutation of SNP
rs1800734 in the MLH1 promoter in COLO320 cells. The top row shows signals from the parental cell line with
clones apparently mutated to AA and GG below. The far-left panel of each row shows the merged signals,
followed by a panel with the chromosome 3 centromere (parental and clone GG) or CRISPR plasmid px330puro
(clone AA) labeled in yellow, two probes flanking MLH1 (RP11-331G2, red; RP11-56P22, green), and a probe
binding directly to the locus (RP11-491D6, blue). Green arrows indicate the position of normal signals, red
abnormal, and blue correct MLH1 signals on an abnormal chromosome. Magnifications (2 · ) of each signal are
embedded into every panel. The graph shows the percentage of cells carrying one, two, or three signals and the
proportion of abnormal signals in each category. All CRISPR AA cells contain at least one abnormal signal
containing the plasmid backbone. Most CRISPR GG cells have two normal MLH1 loci but only one co-labeling with
the chromosome 3 centromere. (B) Reversion of mutation in POLE exon 9 in HCC2998 cells. The top row shows
signals from the parental cell line with clones 1 and 2 with apparent reversion to wild-type sequence shown
below. The far-left panel of each row shows the merged signals, followed by a probes binding to the POLE locus
(RP11-148L11, red), internal between POLE and the centromere (RP11-25J3, green), and telomeric to POLE
(CTC221K18, blue). Green arrows indicate the position of normal signals, red abnormal. Magnifications (2 · ) of
each signal are embedded into every panel. The graph shows the percentage of cells carrying one to five normal
POLE signals per cell in the parental and clones 1 and 2. In clone 1, only one normal signal is seen in the majority
of cells. In clone 2, one normal is seen and one with reduced POLE and no telomeric signal, suggestive of a
truncation breakpoint within the POLE probe binding region.
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that mutations can be quickly and precisely identified in
individual cancer patients, and transferring this genetic
information into cell lines using CRISPR-Cas9 will cre-
ate models in which to develop highly personalized ther-
apies. We found that diploid cancer cells were more
likely to maintain their karyotype during the CRISPR-
Cas9 process, whereas clones from aneuploid parental
cell lines showed high levels of instability due to a com-
bination of their underlying CIN and selection during the
single-cell cloning process.
This study focused on cancer cell lines that are inher-
ently more unstable than primary cells and whole model
organisms. We have not carried out an in-house compar-
ison using our methods on primary cells, and therefore
our conclusions here are limited to cancer cell lines.
It is likely that karyotypic and aneuploid effects will
prove less important in existing and novel CRISPR-Cas9
models with stable genomes such as transgenic mice.
However, chromosomal truncations have recently been
reported after CRISPR-Cas9 in HEK293 cells also
detected by FISH.16 The authors found that using a single
nickase approach reduced the likelihood of truncations,
which presumably arise after failure to repair double-
strand breaks. In addition, large insertions and deletions
in or near the target locus have been previously reported
in mice, mouse embryonic stem cells, and human differ-
entiated cells.7,8 These authors used long-range PCRs and
long-read sequencing spanning up to 30 kb of the target
locus to detect large mutations. Both techniques have
their advantages, and best practice might be to use them
in combination before biological analysis of the final se-
lected clone or transgenic line. Small deletions outside
BACprobeswill bemore easily detected using sequencing,
whereas large deletions >30 kb, chromosome truncations,
and translocations may only be observed using FISH.
The detrimental effects of CIN and large deletions
may vary according to the nature of the planned down-
stream analysis. The fact that many mutations and cancer-
associated variants occur in genes related to genomic in-
tegrity adds additional confounding effects, meaning
that the utility of each clone must be considered on
a case-by-case basis. For instance, in experiment 1, we
wished to observe the effect of mutating a promoter
SNP on transcriptional activation of the adjacent MLH1
promoter in cis. FISH analysis of clone GG showed an in-
tact MLH1 locus, albeit translocated to a different chro-
mosome, making carefully controlled localized in cis
analysis possible. In experiment 2, we aimed to revert
an oncogenic mutation to wild type but instead deleted
the entire oncogenic copy of POLE. Thus, the end result
was still the removal of the mutation and a hemizygous
wild-type clone. Since genes distal to the breakpoint (Sup-
plementary Table S5) were found to be unlikely to affect
replication or repair, and loss of one copy of POLE does
not predispose to cancer,17 selected experiments were
possible on these cell lines. However, in experiment 3,
we wished to assess the effect of reducing NRF2 expres-
sion on resistance to chemo- and radiotherapies. In this
case, the observed karyotypic changes will have far
greater effects on the response to DNA damaging thera-
pies than the intended modest reduction of NRF2 activity.
We propose that novel CRISPR-Cas9 mutated cell
lines or other model systems should only be published
with appropriate combinations of sequencing and cytoge-
netic controls for off-target effects. Simply sequencing
off-target regions predicted by algorithms is not suffi-
cient. Cryptic off-target mutations have been shown to
occur at regions of DNA ‘‘stretching,’’ with up to 10
mismatches to the original guide sequence,18 making it
virtually impossible to rule out undesired mutations. It
should therefore become standard to use multiple clones
or demonstrate the causality of the mutation using rever-
sion experiments in order to confirm that any phenotypic
differences are solely due to targeted mutations.
There are continual advances in CRISPR-Cas9 meth-
odology, and some of these will certainly reduce unwanted
mutations. For example, Cas9 ribonuclear proteins (RNP)
are now routinely used instead of plasmid vectors for
transfection of the CRIPSR machinery into cells.10,12
This route increases efficiency, results in a more transient
Cas9 activity, and will prevent the integration of vector
sequences such as we observed. However, this approach
does not prevent chromosomal rearrangements, as we
have demonstrated. Re-engineering of the Cas9 pro-
tein and modifying the sgRNA scaffold have also been
shown to increase target specificity.19,20 We expect that
more efforts will now be made to limit the instances of
large deletions
In summary, we present a cost-effective visual method
for assessing chromosomal rearrangements and large de-
letions in CRISPR-Cas9 mutated clones. We demonstrate
that these are frequent and significant events in cancer
cell lines, which would have implications for any down-
stream analysis.
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